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Abstract: The efficacy of the plant-derived polyphenol curcumin, in various aspects of health and wellbe-
ing, is matter of public interest. An internet search of the term “Curcumin” displays about 12 million hits.
Among the multitudinous information presented on partly doubtful websites, there are reports attracting
the reader with promises ranging from eternal youth to cures for incurable diseases. Unfortunately, many
of these reports are not based on scientific evidence, but they feed the desideratum of the reader for a
“miracle cure”. This circumstance makes it very difficult for researchers, who work in a scientifically
sound and evidence-based manner on the therapeutic benefits (or side effects) of curcumin, to demarcate
their results from sensational reports that circulate in the web and in other media. This is only one of
many obstacles making it difficult to pave curcumin’s way into clinical application; others are its non-
patentability and low economic usability. A further impediment comes from scientists who never worked
with curcumin or any other natural plant-derived compound in their own labs. They have never tested
these compounds in any scientific assay, neither in vitro nor in vivo; however, they claim, in a sometimes
polemic manner, that everything that has so far been published on curcumin’s molecular effects is based
on artefacts. The here presented Special Issue comprises a collection of five scientifically sound articles
and nine reviews reporting on the therapeutic benefits and the molecular mechanisms of curcumin or
of chemically modified curcumin in various diseases ranging from malignant tumors to chronic diseases,
microbial infection, and even neurodegenerative diseases. The excellent results of the scientific projects
that underlie the five original papers give reason to hope that curcumin will be part of novel treatment
strategies in the near future—either as monotherapy or in combination with other drugs or therapeutic
applications.
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Abstract: The efficacy of the plant-derived polyphenol curcumin, in various aspects of health and
wellbeing, is matter of public interest. An internet search of the term “Curcumin” displays about 12
million hits. Among the multitudinous information presented on partly doubtful websites, there
are reports attracting the reader with promises ranging from eternal youth to cures for incurable
diseases. Unfortunately, many of these reports are not based on scientific evidence, but they feed
the desideratum of the reader for a “miracle cure”. This circumstance makes it very difficult for
researchers, who work in a scientifically sound and evidence-based manner on the therapeutic benefits
(or side effects) of curcumin, to demarcate their results from sensational reports that circulate in the web
and in other media. This is only one of many obstacles making it difficult to pave curcumin’s way into
clinical application; others are its nonpatentability and low economic usability. A further impediment
comes from scientists who never worked with curcumin or any other natural plant-derived compound
in their own labs. They have never tested these compounds in any scientific assay, neither in vitro
nor in vivo; however, they claim, in a sometimes polemic manner, that everything that has so far
been published on curcumin’s molecular effects, is based on artefacts. The here presented Special
Issue comprises a collection of five scientifically sound articles and nine reviews reporting on the
therapeutic benefits and the molecular mechanisms of curcumin or of chemically modified curcumin
in various diseases ranging from malignant tumors to chronic diseases, microbial infection, and
even neurodegenerative diseases. The excellent results of the scientific projects that underlie the five
original papers give reason to hope that curcumin will be part of novel treatment strategies in the
near future—either as monotherapy or in combination with other drugs or therapeutic applications.
1. Curcumin’s Therapeutic Potential and Novel Therapeutic Approaches
The natural polyphenol curcumin is derived from the plant Curcuma longa Linn, a member of
the Zingiberaceae, naturally occurring throughout tropical and subtropical regions of the world.
Curcumin has been used in Ayurveda and traditional Chinese medicine for thousands of years to treat
inflammatory diseases and bacterial infections [1].
1.1. Neoplastic Diseases
Because of its anti-apoptotic and antiproliferative efficacy, its ability to interfere with several tumor
progression associated signaling pathways, and to modulate tumor-associated miRNA expression,
curcumin is regarded as antitumorigenic [2,3]. In addition, curcumin prevents formation of breast and
prostate metastases in vivo [4–6]. The review by Willenbacher et al. in this issue summarizes some
papers that have been published in the field of curcumin’s antitumorigenic effects.
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Curcumin is also potent against cancer types that are difficult to treat, like melanoma [7–9]
or glioblastoma [10], as demonstrated by the work of Maiti et al. in this issue. They observed
increased levels of autophagy and decreased levels of mitophagy markers, along with inhibition of the
PI3K-Akt/mTOR pathway after treatment of glioblastoma cells with curcumin or solid lipid curcumin
particles. Renal cell carcinoma is relatively rare, with rates of approximately 3% of all adult cancer
patients; however, one-third of the patients have metastases at diagnosis and are resistant to most
treatments like chemotherapy or radiation. In this context, complementary and alternative treatment
strategies are highly desiderated by concerned patients. Blaheta and colleagues as well as Zöller and
coworkers describe the very promising effects of a novel therapy combining the application of curcumin
with visible light exposure. In detail, the combination therapy inhibits growth and proliferation of
tumor cells and induces apoptosis.
In the context of curcumin’s molecular modes of action, resulting in its antitumorigenic effects, it
seems likely to draw some attention on its molecular structure. Tomeh and coworkers bring some
light into this aspect by summarizing what is so far known on the correlation between molecular
mechanisms, cellular pathways, and structural characteristics of curcumin and its derivatives.
1.2. Aging
The ability to modulate the transcription factor NFκB explains curcumin’s anti-inflammatory
effect [1,2,11–13]. Aging and age-related diseases also come along with chronic inflammation.
The correlation between cancer and inflammation dates back to Virchow who suggested that
“lymphoreticular” infiltrates reflect the origin of cancer at sites of chronic inflammation, and that there
are striking similarities between ulcers, wound healing, and cancer [14]. The paper by Kujundži´ et al
gives an overview on scientific data that would enable establishing connections and functional links
between the specific of “inflamm-agin” and the cancer cell’s metabolism, its proliferative potential,
and curcumin’s pleiotropic activity. In this context, Bielak-Zmijewska and coworkers also summarize
scientific data on curcumin’s ability to postpone progression of age-related diseases in which cellular
senescence is directly involved. They furthermore point out that curcumin causes elongation of the
lifespan of model organisms and alleviates aging symptoms. In addition, they discuss thoroughly
curcumin’s ability to modulate cellular senescence.
1.3. Inflammatory Disorders
Because of its scientifically evidenced characteristics to interfere with a variety of signal
transduction pathways, transcription factors, and cellular processes, curcumin can potentially be applied
in the treatment of many diseases (inflammatory disorders in particular). In this context, curcumin has
been used to treat gastrointestinal diseases such as indigestion, flatulence diarrhea, and even gastric and
duodenal ulcers [11,15,16]. Kwiecien and colleagues summarize in their review curcumin’s protective
effects against esophageal and gastric disorders. In addition, curcumin is potentially efficacious against
intestinal inflammatory diseases. Burge and colleagues discuss the beneficial effects of curcumin on the
microbiome, its antimicrobial properties, inhibition of TLR4/NFκB/AP-1 signal transduction, changes
in cytokine profiles, and alterations to immune cell maturation and differentiation. The combination of
all these molecular actions makes curcumin a promising candidate to treat intestinal inflammatory
diseases like necrotizing enterocolitis, Crohn’s disease, and ulcerative colitis.
Curcumin can also improve wound healing. Barchitta and coworkers point out that curcumin
induces apoptosis of inflammatory cells during the early phase of wound healing and could accelerate
the healing process by shortening the inflammatory phase. Moreover, curcumin might facilitate
collagen synthesis, fibroblast migration, and differentiation.
1.4. Neurodegenerative Diseases
Lately, evidence has accumulated that curcumin has neuroprotective properties and is a candidate
for the treatment of Alzheimer’s disease. In their review, Pluta and colleagues focus on the
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role and mechanisms of curcumin in inhibiting ischemia/reperfusion brain injury and potential
therapeutic strategies in the treatment of ischemic brain damage of the Alzheimer’s disease phenotype.
Comparably, Ferreira and colleagues also delineate neuroprotective characteristics by summarizing
what is known about the role of curcumin on transthyretin amyloidosis. According to previous reports,
curcumin modulates abnormal transthyretin (TTR) aggregation and inhibits its deposition in the tissue.
The pleiotropic activities of curcumin provide multiple ways to tackle TTR pathophysiology, through
direct interaction of curcumin with TTR, or indirect effects affecting signaling pathways associated
with TTR amyloid fibril formation and clearance.
1.5. Infectious Diseases
The treatment of bacterial infections has become extremely challenging due to resistance against
antibiotics available in the pharmaceutical market. Moreover, another important issue to be addressed
is that common antibiotics evoke adverse events. In this context, phytotherapeutic approaches become
popular for patients who are searching for alternatives to standard treatments. There are numerous
reports that have already delineated not only the antibacterial but also the antiviral and antifungal
activities of curcumin. [17]. In this Special Issue, Czernicka and coworkers focus on the antimicrobial
potential of single components of the Curcuma longa crude extract against a variety of Gram-positive
bacteria strains.
1.6. Remarks on Solubility and Bioavailability
Despite curcumin’s therapeutic potential in vitro and in vivo, it has to be considered that the
molecule is lipophilic and hardly soluble in water. Up to now it is not fully understood how curcumin
reaches the target organ in order to exert its therapeutic effects and how it becomes metabolized in
the human body. In order to overcome these pharmacological problems, several attempts have been
undertaken to encapsulate curcumin into nanoparticles in order to ensure that curcumin is transported
easily in the bloodstream. In the current issue, Kong and coworkers present their data on a novel
formulation of curcumin-loaded mesoporous silica nanoparticles with higher antioxidant activity,
antitumor activity, higher cytotoxicity, and stability as compared to the curcumin molecule itself.
However, cytotoxicity of these nanoparticle carriers has to be explored in depth before we get too
enthusiastic about this idea.
2. Conclusions
In recent years, curcumin’s reputation regarding its therapeutic effects has been damaged.
In molecular drug screening tests, and partly polemic publications, curcumin has been declared to
belong to the PAINS (pan assay interference compounds) [18] and to yield confusing results because
curcumin does not have one single drug target [19]. The authors of these disparagements gained
their information from results generated in high-throughput screenings. However, high-throughput
screenings are prone to technical artefacts and, therefore, are a deceptive tool because potential drug
candidates could be missed. Additionally, the fact that curcumin, like many other natural compounds,
has more than one drug target indicates its versatile applicability and its low risk to cause acquired
therapy resistance [20–22].
A crucial state of mind is prerequisite for good quality of research and every reputable scientist
questions not only the results of other fellow colleagues but also their own. It is our task and
responsibility to provide good quality of research and, of course, it can happen that carelessly executed
research projects and results are published—sometimes even in high ranked papers.
However, this holds true not only for curcumin but also for other bioactive compounds, no matter
if they are plant-derived or if they have been developed and chemically synthesized in Pharma industry.
While reasonable doubt is essential for scientifically sound results, it doesn’t make sense to disparage
everything that has so far been published on curcumin’s therapeutic effects in treating chronic and
neoplastic diseases and to declare that all results are artefacts. Instead, we should accept the challenge
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to distinguish between scientifically sound and false results; otherwise, we lose a promising candidate
for complementary and alternative treatment strategies.
Additionally, we should not challenge treatment successes of Ayurveda or traditional Chinese
medicine, where plant-derived compounds like curcumin have been applied efficaciously to treat
inflammatory diseases and bacterial infections for thousands of years. To disclaim treatment success of
traditional medicine would simply be ignorant.
Curcumin’s detractors criticize that it has never been shown to be conclusively effective in a
randomized, placebo-controlled clinical trial for any indication [19]. To this end it has to be considered
that it is almost impossible to get financial support to conduct a clinical trial with a substance
that cannot be patented and, therefore, is economically uninteresting. Another point is the study
design—curcumin cannot be tested in randomized, placebo-controlled trials because, nowadays,
clinical trials are performed in the form “study compound against standard therapy”, otherwise the
trial would not get a positive vote from the ethics committee. Therefore, the question is: against which
compound should we test curcumin?
There is no doubt, that due to the comprehensive data from preclinical studies, together with
first results from single patients or small cohorts, the next task on the list has to be to test Curcumin
in well-designed clinical trials. However, the greatest challenge will be to find sponsors for clinical
research on curcumin, as this promising plant-derived compound cannot be exploited economically.
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